Production (Stage)
Zenas BioPharma, Inc.
ZBIO
$11.43
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.57M | -52.60M | -38.61M | -37.98M | -27.80M |
| Total Depreciation and Amortization | 23.00K | 33.00K | 36.00K | 35.00K | 33.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.36M | 5.15M | 2.97M | 1.83M | 1.80M |
| Change in Net Operating Assets | -8.86M | 8.87M | 4.54M | 5.16M | 6.87M |
| Cash from Operations | -37.05M | -38.55M | -31.06M | -30.96M | -19.10M |
| Capital Expenditure | -18.00K | -74.00K | 0.00 | -35.00K | -22.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -86.26M | -3.66M | -26.76M | -- | -- |
| Cash from Investing | -86.27M | -3.74M | -26.76M | -35.00K | -22.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 99.00K | 6.33M | 234.42M | 124.00K | 42.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 178.38M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -4.47M | -439.00K | -766.00K | -656.00K |
| Cash from Financing | 99.00K | 1.85M | 233.98M | 177.74M | -614.00K |
| Foreign Exchange rate Adjustments | -52.00K | 141.00K | -52.00K | 32.00K | 36.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.28M | -40.30M | 176.11M | 146.78M | -19.70M |